This study reveals the previously uncharacterized of ZNF281 in promoting androgen receptor–dependent transcription and androgen receptor-independent proliferative and metastatic programs in prostate cancer, advances understanding of disease progression across different androgen receptor expression statuses, and establishes pharmacologic ZNF281 inhibition as a therapeutic strategy for metastatic prostate cancer.
Loss of tumor suppressors can drive carcinogenesis while simultaneously creating actionable therapeutic vulnerabilities. Epidermal growth factor receptor (EGFR) is frequently overexpressed in prostate cancer (PCa), yet EGFR inhibitors have shown limited clinical benefit, and the basis for this variability remains uncle...
Yong-Hong Liu, Zhang-Wei Tong, Q. Mo et al.· Nature Communications· 0 citations
It is implied that in prostate cancer, the DNHD1-HDAC6 axis, a novel regulatory pathway, promotes aggressiveness and that HDAC6 is a targetable mediator of DNHD1-driven malignancy.
An-Nie-On-Nei Lee, Chia-Chang Wu, Su-Wei Hu et al.· Oncology Report· 0 citations
These findings establish AR phase separation as a fundamental mechanism driving GC pathogenesis and propose co-targeting AR condensates and chromatin remodeling as a translatable therapeutic strategy.
Hua-Huan Liu, Yan-Xin Yao, Xiang-Nan Zhang et al.· Cell Death & Disease· 0 citations
FST-Trap is developed, which effectively neutralizes FST, resensitizes resistant tumors to AR-targeted therapy, and enhances immunotherapy efficacy, establishing FST as both a biomarker and therapeutic target for AR-independent prostate cancer.
Xiao-Xian Shi, Zu-Yan Fan, Min Qu et al.· Proceedings of the National...· 0 citations
Abstract The development of liver metastases in prostate cancer is associated with aggressive disease and poor prognosis. Because hepatocytes exhibit high metabolic activity with unique secretory profiles, we hypothesized that hepatocyte-to-tumor cell signaling plays a role in promoting liver metastasis. We evaluated s...
Jacob Egelberg, Rebecca Kim, M. J. Kim et al.· Cancer Research Communicatio...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.